Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens

Journal of Human Virology

Volumn 4, Issue 6, 2001, Pages 306-316

  Kmieciak, Dariusz ^a   Bolesta, Elizabeth ^a   Naito, Toshio ^a   Gzyl, Jaroslaw ^a   Kaneko, Yutaro ^a   Kozbor, Danuta ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

gag pol; HIV 1; Vaccine

Indexed keywords

GAG PROTEIN; HYBRID PROTEIN; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELL MEMBRANE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; FRAMESHIFT MUTATION; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; GENE EXPRESSION; GENE PRODUCTS, GAG; GENETIC VECTORS; H-2 ANTIGENS; HELA CELLS; HIV ANTIBODIES; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; JURKAT CELLS; MICE; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL PROTEINS; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; VACCINIA VIRUS;

EID: 0035742626     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
2. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
3. + T cells with a predominant V beta usage during the primary immune response to HIV
4. Cytotoxic T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
5. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
6. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant
7. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients
8. + T-helper and a T-killer cell
9. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
10. + T cell responses associated with control of viremia
11. Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection
12. Protective role of β-chemokines associated with HIV-specific Th responses against perinatal HIV transmission
13. Antigenic oscillations and shifting immunodominance in HIV-1 infections
14. T cell responses and viral escape
15. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
16. Cross-clade T cell recognition of HIV
17. Control of a mucosal challenge and prevention of AIDS by a multi-protein DNA/MVA vaccine
18. An endoplasmic reticulumtargeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope
19. HIV expression strategies: Ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems
20. + cytotoxic T lymphocyte responses in seronegative volunteers
21. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
22. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression
23. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes
24. Vaccinia virus expression vector: Coexpression of beta-galactosidase provides visual screening of recombinant virus plaques
25. Longterm culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1
26. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells
27. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
28. Characterization of HLA-A 0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein
29. The effect of epitope variation on the profile of cytotoxic T lymphocyte responses to the HIV envelope glycoprotein
30. Human immunodeficiency virus-like particles produced by vaccinia virus expression vector
31. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: Analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses
32. Vaccinia virus: A selectable eukaryotic cloning and expression vector
33. A bipartite membrane-binding signal in the human immunodeficiency virus type-1 matrix protein is required for the proteolytic processing of Gag precursors in a cell type-dependent manner
34. The effect of deletion of the V3 loop of gp120 on cytotoxic T cell responses and HIV gp120-mediated pathogenesis
35. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV
36. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8
37. Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus
38. + T cells using an ELISPOT assay
39. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice
40. Oral immunization with hepatitis B surface antigen expressed in transgenic plants
41. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 Gag by using DNA expression vectors that target Gag antigen to the secretory pathway
42. Synthesis of the CC-chemokines MIP-1 α, MIP-1 β, and RANTES is associated with a type 1 immune response
43. Naive and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: Implications for transmission and pathogenesis
44. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein
45. Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammes MVA
46. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
47. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus ankara boost vaccination regimen
48. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant poxvirus booster immunizations